As Joe Papa begins the difficult task this week of reviving Valeant Pharmaceuticals, he may want to start by repairing relations with hospitals. The drug maker angered many hospital officials early ...

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) revealed that it would make available an enhanced rebate program to cut the prices of Nitropress, as well as, Isuprel. The move comes after a ...

(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY), an integrated pharmaceutical company, announced the launch of Sodium Nitroprusside Injection single-dose Vial, the therapeutic generic equivalent of ...

The Food and Drug Administration has approved a generic version of Valeant Pharmaceuticals' heart drug Nitropress, according to its website, and shares of Valeant are down almost 5% on the news. "This ...

LAVAL, Quebec, Sept. 16, 2016 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") seeks to clarify statements made in a media report today. Pursuant to a ...

Valeant Pharmaceuticals on Monday said it will offer hospitals deeper discounts for the heart drugs Nitropress and Isuprel, with hospitals now eligible for rebates between 10 and 40 percent based on ...

Here’s a solution for the hospitals that say they’re still waiting on the discounts Valeant promised for price-jacked heart med Nitropress: The FDA has approved a generic. The agency green-lighted the ...

On Thursday, Valeant Pharmaceuticals' interim CEO, Howard Schiller, will testify before Congress on his company's drug-pricing practices. You can expect there to be some heated words from the ...